The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of Lotemax ophthalmic suspension 0.5%
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
140
Ocular administration of study drug. at least once within any indication of the label.
Ocular administration of study drug. at least once within any indication of the label.
Bausch & Lomb Korea Ltd
Seoul, South Korea
Safety
All adverse events that occurred from the first dose of the study drug regardless of causality to the study drug. Changes in all undesirable medical findings and all adverse events occurring with the use of the study drug.
Time frame: 4 years
Seasonal Allergic Conjunctivitis
Signs and symptoms of seasonal allergic conjunctivitis: The efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.
Time frame: 4 years
Giant Papillary Conjunctivitis
Signs and symptoms of giant papillary conjunctivitis: The results of the efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.
Time frame: 4 years
Post-operative inflammation
Treatment of post-operative inflammation following ocular surgery: The results of the final efficacy assessment will be evaluated according to the classification: improved, unchanged, worsened, impossible to assess.
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.